The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
|Videos|November 9, 2017
Evolving Paradigm of Gastrointestinal Cancers
Author(s)John L. Marshall, MD
John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the evolving paradigm of gastrointestinal cancers.
Advertisement
Advertisement
Related to this article
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
2
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5